Good Morning Market Enthusiast,

Quick update on MAIA Biotechnology (NYSE American: MAIA): this name is back in the headlines, and you’ll want to check them out right now.

The company just secured a $2.3 million grant from the National Institutes of Health to expand its pivotal Phase 2 THIO-101 trial into the United States. (20)

(19)

For a micro-cap biotech, this isn’t noise — it’s confirmation that one of the most respected institutions in the world sees enough promise in MAIA’s science to put millions behind it.

Why This NIH Grant Matters (20)(21)

The capital at this stage is a game-changer. With this grant, the NIH is helping fund U.S. enrollment in THIO’s clinical path for patients who are resistant to both chemo and immunotherapy. That’s the exact population with no standard of care and the highest unmet medical need.

And the timeline isn’t abstract:
✅ Grant funds flow through 2027, locking in trial support
✅ FDA IND clearance means U.S. enrollment starts immediately
✅ First expansion patients already dosed in Taiwan this summer

The Clinical Signal (21)

The science here is not hypothetical. In third-line NSCLC patients:

🔬 Median overall survival hit 17.8 months as of June — nearly triple the 5–6 months chemo usually delivers.
💥 This is efficacy data no other therapy in this setting has matched.

That’s why the NIH stepped up. 

Market Implications (21)

Here’s where things get interesting. MAIA is no stranger to big moves: this year alone, it’s already delivered multiple separate surges, some in the double digits intraday. With a thin float, catalysts like this tend to get priced in fast.

Stack this with:

• Fast Track designation already in play — accelerating potential approval timelines.
   
• Global trial footprint expanding across Asia and the U.S. for credibility and patient scale.
   
• Big pharma engagement (Roche, Regeneron) validating the science.
   

The Setup Right Now

With NIH dollars flowing in, MAIA gets to push its trial forward.

This isn’t just another headline — it’s a signal that the science is real, the funding is real, and the timeline to broader recognition is collapsing.

🕒 Momentum plus NIH validation is the kind of setup that doesn’t stay quiet.

Keep MAIA Biotechnology (NYSE American: MAIA) in sharp focus — history suggests when MAIA starts moving, it doesn’t wait around.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://bit.ly/4cLWaog

2. https://bit.ly/4cRuZZk

3. https://bit.ly/42pGNOM

4. https://bit.ly/4cVjJLl

5. https://bit.ly/4jmedDM

6. https://bit.ly/3GjzjEx

7. https://bit.ly/4lIXYlV
8. https://bit.ly/4lKdluq
9. https://bit.ly/3GminNn

10. https://finance.yahoo.com/news/maia-biotechnology-announces-first-patient-131500434.html
11. https://finance.yahoo.com/news/maia-biotechnology-announces-peer-reviewed-131700117.html
12. https://finance.yahoo.com/news/maia-biotechnology-receives-fda-fast-120100331.html
13. https://finance.yahoo.com/news/maia-biotechnology-granted-european-patent-130100345.html

14. https://finance.yahoo.com/news/diamond-equity-research-releases-note-120000909.html

15. https://ml.globenewswire.com/Resource/Download/b5e1fff3-02a0-4a78-b533-2ec8845f612e

16. https://finance.yahoo.com/news/maia-biotechnology-announces-publication-interim-130100253.html
17. https://finance.yahoo.com/news/maia-biotechnology-abstract-selected-poster-130300068.html

18. https://maiabiotech.com/
19. https://ir.maiabiotech.com/company-information/presentations
20. https://finance.yahoo.com/news/maia-biotechnology-awarded-2-3-120100527.html
21. https://ir.maiabiotech.com/

Momentum Media LLC has not been compensated for today's profile on MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been previously hired for a period beginning on 09/10/2025 and ending on 09/11/2025 (the “Campaign”) to publicly disseminate information about MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been compensated $7,500.00 and are owed an additional $0 for the Campaign. To date, we have been paid $69,600.00. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.